Core Insights - Alphatec Holdings, Inc. (ATEC) has secured exclusive U.S. rights to market and distribute Theradaptive's OsteoAdapt® platform, marking a significant partnership in the spine industry aimed at enhancing spinal fusion outcomes [2][4] - Theradaptive has initiated a Series B investment round to support the expansion of its protein-engineering technology and the advancement of clinical studies related to OsteoAdapt [5][6] Company Overview - ATEC is focused on revolutionizing spine surgery through innovative solutions and has developed a procedural ecosystem that integrates informatics, imaging, navigation, and instrumentation [4][7] - Theradaptive is a clinical-stage regenerative medicine company that specializes in engineered protein therapeutics for various medical applications, including spine and orthopedic treatments [8] Technology and Market Potential - OsteoAdapt utilizes proprietary AMP2™ protein technology and is currently undergoing clinical trials, having received three FDA Breakthrough Device Designations, indicating its potential to meet significant medical needs in bone regeneration [3][6] - The U.S. spine surgery market exceeds $10 billion annually, with the biologics segment representing a $2+ billion opportunity, positioning OsteoAdapt as a transformative solution in the market [6]